MFGP
NAMS icon

Marshall Financial Group (Pennsylvania)’s NewAmsterdam Pharma NAMS Stock Holding History

Marshall Financial Group (Pennsylvania)’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$213K Buy
+7,500
New +$180K 0.06% 52

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Marshall Financial Group (Pennsylvania)'s NAMS Position: Q3 2025 in Review

Marshall Financial Group (Pennsylvania) opened a new position in NewAmsterdam Pharma (NAMS) in Q3 2025: 7,500 shares worth $213K. The stake represents 0.06% of the portfolio and ranks #52 among its holdings.

137 funds tracked by Wall St. Rank hold NAMS as of Q3 2025.

  • Marshall Financial Group (Pennsylvania) held 7,500 shares of NewAmsterdam Pharma worth $213K as of Q3 2025.
  • NewAmsterdam Pharma was a new Marshall Financial Group (Pennsylvania) position in Q3 2025.
  • NewAmsterdam Pharma made up 0.06% of Marshall Financial Group (Pennsylvania)'s portfolio in Q3 2025, its #52 holding.
  • 137 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2025.

Based on Marshall Financial Group (Pennsylvania)'s 13F filing for Q3 2025, filed 4 Nov 2025.